

LECANEMAB APPROPRIATE USE RECOMMENDATIONS

These appropriate use recommendations (AURs) are for the use of lecanemab for the treatment of early AD (ie, MCI due to AD or mild AD dementia) with confirmed brain amyloid pathology based on the clinical guidance developed by the Alzheimer's Disease and Related Disorders Therapeutics Working Group and the FDA Prescribing Information for lecanemab. This piece is part of an appropriate use toolkit independently developed by the Alzheimer's Association for HCPs who have decided to offer lecanemab for a patient meeting eligibility criteria. These AURs apply to lecanemab; other anti-amyloid monoclonal antibodies may have different management requirements. AURs specific to the monoclonal antibody being considered should be referenced.

Review this section of the toolkit to learn more about the radiographic grading and type of ARIA, monitoring and ongoing management, accompanying symptoms, and when lecanemab discontinuation may be appropriate.

Management of ARIA




A non-contrast MRI, utilizing T1 FLAIR and T2*-weighted GRE or equivalent sequences (such as SWI), and DWI, preferably on a 3T magnet should be obtained. Two types of amyloid-related imaging abnormalities (ARIA) can occur: ARIA-E with edema and ARIA-H with hemorrhagic changes. In the CLARITY AD phase 3 trial of lecanemab, rates of ARIA for those on lecanemab were 12.6% for ARIA-E and 17.3% for ARIA-H vs 1.7% and 9.0%, respectively, for those on placebo.

Description of mild, moderate, and severe radiographic ARIA (from the Prescribing Information)

ARIA Type	Radiographic Severity		
	Mild	Moderate	Severe
ARIA-E	FLAIR hyperintensity confined to sulcus and/or cortex/subcortex white matter in 1 location <5 cm	FLAIR hyperintensity 5 to 10 cm in single greatest dimension, or more than 1 site of involvement, each measuring <10 cm	FLAIR hyperintensity >10 cm with associated gyral swelling and sulcal effacement. One or more separate/independent sites of involvement may be noted
ARIA-H Microhemorrhage	≤4 new incident microhemorrhages	5 to 9 new incident microhemorrhages	10 or more new incident microhemorrhages
ARIA-H Superficial Siderosis	1 focal area of superficial siderosis	2 focal areas of superficial siderosis	>2 areas of superficial siderosis

Monitoring and management of ARIA



AD, Alzheimer's disease; ARIA, amyloid-related imaging abnormalities; ARIA-E, ARIA with edema; ARIA-H, ARIA with hemorrhagic changes; DWI, diffusion-weighted imaging; FLAIR, fluid attenuated inversion recovery; GRE, gradient recalled echo; HCP, healthcare provider; MCI, mild cognitive impairment; MRI, magnetic resonance imaging; SWI, susceptibility weighted imaging.

Cummings J, Apostolova L, Rabinovici GD, et al. Lecanemab: appropriate use recommendations. *J Prev Alzheimers Dis.* 2023;10(3):362-377. doi:10.14283/jpad.2023.30

This work is licensed under Creative Commons Attribution 4.0 International License <http://creativecommons.org/licenses/by/4.0/>

LECANEMAB APPROPRIATE USE RECOMMENDATIONS

These appropriate use recommendations (AURs) are for the use of lecanemab for the treatment of early AD (ie, MCI due to AD or mild AD dementia) with confirmed brain amyloid pathology based on the clinical guidance developed by the Alzheimer's Disease and Related Disorders Therapeutics Working Group and the FDA Prescribing Information for lecanemab. This piece is part of an appropriate use toolkit independently developed by the Alzheimer's Association for HCPs who have decided to offer lecanemab for a patient meeting eligibility criteria. These AURs apply to lecanemab; other anti-amyloid monoclonal antibodies may have different management requirements. AURs specific to the monoclonal antibody being considered should be referenced.

Review this section of the toolkit to learn more about the radiographic grading and type of ARIA, monitoring and ongoing management, accompanying symptoms, and when lecanemab discontinuation may be appropriate.

Management of ARIA (cont'd)



Symptoms observed in patients who develop symptomatic ARIA

- Headache
- Confusion
- Visual changes
- Dizziness
- Nausea
- Gait difficulty
- Serious ARIA
 - Seizures
 - Status epilepticus
 - Encephalopathy
 - Stupor
 - Focal neurological deficits

Management of ARIA depending on the severity of symptoms and the severity of the radiographic ARIA-E or ARIA-H on MRI

	Symptom Description			
	No Symptoms	Mild Symptoms	Moderate Symptoms	Severe Symptoms
Severity of changes observed on MRI	None	Discomfort noted; no disruption of daily activity	Discomfort sufficient to reduce or affect normal daily activity	Incapacitating, with inability to work or to perform normal daily activity
ARIA-E on MRI				
Mild	Continue dosing	Suspend dosing	Suspend dosing	Discontinue dosing
Moderate	Suspend dosing	Suspend dosing	Suspend dosing	Discontinue dosing
Severe	Discontinue dosing	Discontinue dosing	Discontinue dosing	Discontinue dosing
ARIA-H on MRI				
Mild	Continue dosing	Suspend dosing	Suspend dosing	Discontinue dosing
Moderate	Suspend dosing	Suspend dosing	Suspend dosing	Discontinue dosing
Severe	Discontinue dosing	Discontinue dosing	Discontinue dosing	Discontinue dosing

Please scan or click below to view the full Prescribing Information for lecanemab



Please scan or click below to view the lecanemab appropriate use recommendations publication



AD, Alzheimer's disease; ARIA, amyloid-related imaging abnormalities; ARIA-E, ARIA with edema; ARIA-H, ARIA with hemorrhagic changes; HCP, healthcare provider; MCI, mild cognitive impairment; MRI, magnetic resonance imaging.

Cummings J, Apostolova L, Rabinovici GD, et al. Lecanemab: appropriate use recommendations. *J Prev Alzheimers Dis.* 2023;10(3):362-377. doi:10.14283/jpad.2023.30

This work is licensed under Creative Commons Attribution 4.0 International License <http://creativecommons.org/licenses/by/4.0/>